Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory Disorders
David Harrison(Chelmsford and Essex Hospital), Alan P. Watt(Essex Cardiothoracic Centre), Andy Billinton(Chelmsford and Essex Hospital), Valérie Reader(Chelmsford and Essex Hospital), Jane Scanlon(Chelmsford and Essex Hospital), John R. Doedens(Univera (United States)), Christopher A. Gabel(Community Health Systems - Lutheran Hospital), Mark G. Bock, M. Katharine Holloway, Kenneth Schooley, Roderick A. Porter(Ashwell Museum)
Cited by 62
Related Papers
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
|Nature Biotechnology|2011|666
Ubiquitin Ligase Substrate Identification through Quantitative Proteomics at Both the Protein and Peptide Levels
|Journal of Biological Chemistry|2011|85
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing
|European Journal of Pharmacology|2014|54
Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796
|Journal of Pharmacology and Experimental Therapeutics|2024|51